Peer-reviewedCC BY 4.0Cell reports
B cell responses to CD40 stimulation ignite anti-tumor immunity by activating CD8+ T cell cytotoxicity
9 affiliations
- 1Nomis Center for Immunobiology and Microbial Pathogenesis, Salk Cancer Center, Salk Institute for Biological Studies, La Jolla, CA 92037, USA
- 2University of California, San Diego, School of Biological Sciences, San Diego, CA 92093, USA
- 3These authors contributed equally
- 4Waitt Advanced Biophotonics Center Core Facility, Salk Institute for Biological Studies, La Jolla, CA 92037, USA
- 5University of California, San Diego, Department of Radiation Medicine & Applied Sciences, San Diego, CA 92093, USA
- 6Department of Systems Biology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
- 7BC Cancer Deeley Research Centre, Victoria, BC V8R 6V5, Canada
- 8Senior author
- 9Lead contact
Abstract
SUMMARY: B cell responses to cancer are critical to patient survival and response to therapy. Yet, the knowledge as to how B cells can elicit anti-tumor immunity remains incomplete. We identify that CD40 pathway activation in B cells in the presence of high tumor mutation burdens activates an anti-tumor B cell response. Significantly, our study shows that CD40-stimulated B cells drive tumor infiltration, organization, and activation of cytotoxic function in CD8+ T cells. These results provide key advances in the mechanistic regulation and function of B cell and CD8+ T cell responses to cancer.
Related
- CX3CR1+ microglia/macrophages, activated T cells, and IFN-γ-driven stimulation confer age-dependent protective immunity in young-adult mice following β-coronavirus infection.
- Irrigation fluid absorption induces metabolic and oxidative stress dysregulation activating NLRP3 and NF-κB pathways to drive hippocampal inflammatory responses
- Mancozeb induces cytotoxicity and functional impairment in bovine mammary epithelial cells through ER stress, oxidative stress, and inflammatory responses
- Dynamic EEG network responses to acupuncture stimulation in patients with stroke: a neurophysiological study
- A randomised, placebo-controlled study to assess whether antibiotic-mediated disruption of the gut microbiota impairs BCG-induced specific and non-specific immunity in young, healthy adults: protocol for the Antibiotics and Vaccine Immune Responses Study (AVIRS).
BibTeX
@article{nguyen2026cell,
title = {{B cell responses to CD40 stimulation ignite anti-tumor immunity by activating CD8+ T cell cytotoxicity}},
author = {Kendrick Nguyen and Monika Quackenbush and Sara Basbous and Haley Rodriguez and Georgia Lattanzi and Elsie Quansah and Chynna Bowman and Sammy Weiser Novak and Daniela Boassa and Jingting Yu and Taylor Ozbun and Asona Lui and Aatish Thennavan and Peter Watson and April Wehner and Daniel Hollern},
journal = {Cell reports},
year = {2026},
month = sep,
doi = {10.1016/j.celrep.2026.117957},
url = {https://doi.org/10.1016/j.celrep.2026.117957},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - B cell responses to CD40 stimulation ignite anti-tumor immunity by activating CD8+ T cell cytotoxicity
AU - Kendrick Nguyen
AU - Monika Quackenbush
AU - Sara Basbous
AU - Haley Rodriguez
AU - Georgia Lattanzi
AU - Elsie Quansah
AU - Chynna Bowman
AU - Sammy Weiser Novak
AU - Daniela Boassa
AU - Jingting Yu
AU - Taylor Ozbun
AU - Asona Lui
AU - Aatish Thennavan
AU - Peter Watson
AU - April Wehner
AU - Daniel Hollern
PY - 2026
DA - 2026/09/11
JO - Cell reports
DO - 10.1016/j.celrep.2026.117957
UR - https://doi.org/10.1016/j.celrep.2026.117957
AB - SUMMARY: B cell responses to cancer are critical to patient survival and response to therapy. Yet, the knowledge as to how B cells can elicit anti-tumor immunity remains incomplete. We identify that CD40 pathway activation in B cells in the presence of high tumor mutation burdens activates an anti-tumor B cell response. Significantly, our study shows that CD40-stimulated B cells drive tumor infiltration, organization, and activation of cytotoxic function in CD8+ T cells. These results provide key advances in the mechanistic regulation and function of B cell and CD8+ T cell responses to cancer.
SN - 2211-1247
ER -